drugset / Trial / NCT05575986
Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of hetrombopag in the treatment of thrombocytopenia after chemotherapy in patients with digestive system malignant tumors
Timeline
- Start
- 2022-10
- Primary completion
- 2023-10
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hetrombopag Olamine | Unknown | 7.5 mg | Oral |